The 24 references in paper E. Kunder V., M. Volkova V., I. Generalov I., G. Nevinsky A., Е. Кундер В., М. Волкова В., И. Генералов И., Г. Невинский А. (2014) “КЛИНИКО-ПАТОГЕНЕТИЧЕСКАЯ И ДИАГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ ДЕЗОКСИРИБОНУКЛЕАЗНОЙ АКТИВНОСТИ ПОЛИКЛОНАЛЬНЫХ IGG И СЫВОРОТКИ КРОВИ ПРИ СПОНДИЛОАРТРИТАХ // CLINICAL AND DIAGNOSTIC SIGNIFICANCE OF DEOXYRIBONUCLEASE ACTIVITY OF POLYCLONAL IgG AND BLOOD SERA IN PATIENTS WITH SPONDYLOARTHRITIS” / spz:neicon:mimmun:y:2012:i:5:p:337-346

1
Генералов И.И., Сидорская Е.В. Абзимная активность препаратов IgG у больных ревматоидным артритом и системной красной волчанкой // Иммунология. – 1998. – No 3. – С. 54-56.
(check this in PDF content)
2
Мальцев К.А., Хитров А.Н., Введенская О.Ю., Пономаренко Н.А., Исаева М.А., Кимова М.В., Третьяк Е.Б., Шогенов З.С., Алекберова З.С., Габибов А.Г., Сучков С.В. Каталитические аутоантитела – новый молекулярный инструмент в кардиологии и офтальмологии // Тер. архив. – 2006. – No 11. – С. 70-76.
(check this in PDF content)
3
Насонов Е.Л., Александрова Е.Н. Современные стандарты лабораторной диагностики ревматических заболеваний. Москва, 2006. – 70 с.
(check this in PDF content)
4
Невинский Г.А., Канышкова Т.Г., Бунева В.Н. Природные каталитически активные антитела (абзимы) в норме и при патологии // Биохимия. – 2000. – No 65. – С. 1245-1255.
(check this in PDF content)
5
Способ определения ДНКазной активности: пат. 243А Респ. Беларусь, МПК С12 Q1/34, С 12 N 9/22 / К.С. Азаренок, И.И. Генералов, А.Г. Голубева, Н.В. Железняк, М.Р. Конорев; 1996. – No 3. – С. 174.
(check this in PDF content)
6
Способ очистки иммуноглобулинов класса G из сыворотки крови и устройство для аффинной хроматографии: пат. 3205 Респ. Беларусь, МПК 6G 01 N 33/48 / М.Р. Конорев, И.И. Генералов, И.В. Жильцов, А.Г. Генералова; 1999. – No 3. – С. 121.
(check this in PDF content)
7
Хитров А.Н. ДНК-абзимы при ревматоидном артрите: патогенетическое и клиническое значение // Тер. архив. – 2005. – No 77. – С. 75-80.
(check this in PDF content)
8
Akkoc N. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? // Curr. Rheumatol. Rep. – 2008. – Vol. 10. – P. 371-378.
(check this in PDF content)
9
Bergman M.J. Social and economic impact of inflammatory arthritis // Postgrad. Med. – 2006. – Vol. 5. – P. 8-11.
(check this in PDF content)
10
Braun J., Kingsley G., van der Heijde D., Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive arthritis // J. Rheumatol. – 2000. – Vol. 27. – P. 2185-2192.
(check this in PDF content)
11
Calzavara-Pinton P.G., Franceschini F., Manera C. Incidence of antiperinuclear factor in patients with psoriatic arthritis // Adv. Exp. Med. Biol. – 1999. – Vol. 455. – P. 215-220.
(check this in PDF content)
12
Chen C.H., Yu D.T., Chou C.T. Biomarkers in spondyloarthropathies // Adv. Exp. Med. Biol. – 2009. – Vol. 649. – P. 122-132.
(check this in PDF content)
13
Dougados M., van der Linder S., Juhlin R., Huitfeldt B., Amor B., Calin A., Cats A., Dijkmans B., Olivieri I., Pasero G. The European Spondyloarthropathy Study Group preliminary criteria for classification of spondyloarthropathy // Arthritis Rheum. – 1991. – Vol. 34. – P. 1218-1227.
(check this in PDF content)
14
Healy P.J., Helliwell P.S. Classification of the spondyloarthropathies // Curr. Opin. Rheumatol. – 2005. – Vol. 17. – P. 393-395.
(check this in PDF content)
15
Johnson S.R., Schentag C.T., Gladman D.D. Autoantibodies in biological agents nave patients with psoriatic arthritis // Ann. Rheum.Dis. – 2005. – Vol. 64. – P. 770-772.
(check this in PDF content)
16
Kavanaugh A., Solomon D.H., Schur P., American college of rheumatology ad hoc committee on immunologic testing guidelines Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction // Arthritis Rheum. – 2002. – Vol. 47. – P. 429-433.
(check this in PDF content)
17
Kawai Y., Yoshida M., Arawaka K., Kumamoto T., Morikawa N., Masamura K., Tada H., Ito S., Hoshizaki H., Oshima S., Taniguchi K., Terasawa H., Miyamori I., Kishi K., Yasuda T. Diagnostic Use of Serum Deoxyribonuclease I Activity as a Novel Early-Phase Marker in Acute Myocardial Infarction // Circulation. – 2004. – Vol. 109. – P. 2398-2400.
(check this in PDF content)
18
Kozyr A.V., Kolesnikov A.V., Zelenova N.A., Sashenko L.P., Mikhalap S.V., Bulina M.E., Ignatova A.N., Favorov P.V., Gabibov A.G. Autoantibodies to nuclear antigens: correlation between cytotoxicity and DNA-hydrolyzing activity // Appl. Biochem Biotechnol. – 2000. – Vol. 83. – P. 255-268.
(check this in PDF content)
19
Rader C., List B. Catalytic antibodies as magic bullets // Chemistry. – 2000. – Vol. 12. – P. 2091-2095.
(check this in PDF content)
20
Sallai K., Nagy E., Derfalvy B., Muzes G., Gergely P. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus // Clinical and Diagnostic Laboratory Immunology. – 2005. – Vol. 1. – P. 56-59.
(check this in PDF content)
21
Shojania K. What laboratory tests are needed? // CMAJ. – 2000. – Vol. 162. – P. 743-746.
(check this in PDF content)
22
Suchkov S.V., Gabibiv A.G., Gnuchev N.V. Phenomenon of DNA-abzyme cross-reactivity and its significance for the mechanisms of cytotoxicity and apoptosis // Ontogenez. – 2001. – Vol. 32. – P. 348-352.
(check this in PDF content)
23
Taylor W., Gladman D.D., Helliwell P., Marchesoni A., Mease P., Mielants H. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study // Ann. Rheum. Dis. – 2006. – Vol. 54. – P. 2665-2673.
(check this in PDF content)
24
Linder S., Valkenburg H.A., Cat Valkenburgs A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria // Arthritis Rheum. – 1984. – Vol. 2. – P. 361-368.
(check this in PDF content)